

RaDistance Safety Meter PDS

Updated: September 19, 2014

Client:

Dr. Sarah Hagi – sarahhagi@gmail.com

Dr. John Webster – webster@engr.wisc.edu

Advisor:

Dr. Walter Block – wfblock@wisc.edu

Members:

Nick Gilling – ngilling@wisc.edu

Alex Mccunn – mccunn@wisc.edu

Michael Wolff – mbwolff2@wisc.edu

Keith Dodd – dodd2@wisc.edu

Joe Benthein – benthein@wisc.edu

Problem Statement: Patients treated with therapeutic doses of radioactive iodine (I-131) can be potentially harmful to those in close proximity when discharged. The radiation from the doses can be a threat to those less than one meter away from the patient, especially family members and healthcare providers who are in frequent contact. Our client, Dr. Sarah Hagi, from the radiology department at King Abdulaziz University Hospital, requested a device that alerts the patient if individuals are within one meter. We would like to create a device that will provide feedback to alert patients of their proximity around others, and also to alert the patient's family members of overall radiation exposure.

Client Requirement:

- Must be able to sense a human within a one-meter range.
- Must provide a feedback to alert the patient.
- Must be comfortable enough to wear on a day-to-day basis.

1. Physical and Operational Characteristics

- a. Performance requirements:** Must detect human presence, and possibly pets, within one meter for at least 6 weeks. Must provide feedback to alert user of human presence. Must function under mild radioactive conditions. Device to be used on 20 patients per year.
- b. Safety:** The device must have sufficient feedback mechanism to warn user of unsafe distances with minimal discomfort to the user. The materials must not become radioactive in the period of use. Electrical components must be concealed.
- c. Accuracy and Reliability:** The device must be battery powered and function accurately for at least 6 weeks. The device must detect distances within a 0.1 meter tolerance.

- d. Life in Service:** When the patient is discharged from the hospital after therapeutic radioactive iodine treatment it is recommended they avoid coming within one meter of another person for 4-6 weeks. The device would have to be constantly active for this period of time. It is possible it could be recharged at night while the patient is sleeping. The device should hold a charge for at least 17 hours/day, 7 days a week for 6 weeks.
- e. Shelf Life:** The device should be able to be stored for 10 years without using any of its functionality.
- f. Operating Environment:** The device will be operated in various interior and exterior environments throughout the world. For this reason it should ideally be operational at extreme temperature (-25-50 degrees Celsius) and humidity (5-95%) ranges. It should also be water resistant in the event of rain or spilling.
- g. Ergonomics:** The device must be comfortable to wear throughout the day for up to six weeks.
- h. Size:** The device must be small enough not to intrude on the patient's daily activities.
- i. Weight:** The device must be light enough to be worn comfortably on the patient. The device should weigh no more than one kilogram.
- j. Materials:** The materials must not be affected by radiation from I-131. The device should not be made out of a common allergen, such as latex. Electrical components should maintain their electrical properties in the presence of radiation.
- k. Aesthetics, Appearance, and Finish:** The device should be aesthetically appealing so that the patient feels comfortable wearing the device.

2. Production Characteristics

- a. Quantity:** One Prototype.
- b. Target Product Cost:** Around \$100.

3. Miscellaneous

- a. Standards and Specifications:** The device must meet the requirements of the National Institute of Standards and Technology.
- b. Customer:** Therapeutic iodine radiation clinics and hospitals and the patients they treat.

- c. Patient-related concerns:** The device needs to be durable and comfortable.
- d. Competition:** There are no devices currently on the market targeted towards therapeutic radioactive iodine patients.